{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:39:15Z","timestamp":1758191955801,"version":"3.44.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"crossref","award":["Financial Support"],"award-info":[{"award-number":["Financial Support"]}],"id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To clarify the effect of intravitreal aflibercept injections in patients with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) presenting with best-corrected visual acuity (BCVA) better than 20\/40.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This prospective study included 61 eyes of 44 patients with BRVO and 17 patients with CRVO with untreated macular edema. Patients whose macular edema improved within 3 months through the natural course were excluded. Patients were administered intravitreal aflibercept injections following a treat-and-extend regimen in which treatment intervals were adjusted every 4 weeks based on BCVA and central retinal thickness stability. BCVA and central retinal thickness were measured before and up to 12 months. Retinal sensitivity measured by microperimetry and mean deviation values from the Humphrey 30-2 visual field analyzer were evaluated at baseline and 6 and 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirty-five patients with BRVO and 14 patients with CRVO completed the study. For patients with BRVO, the mean BCVA (logarithm of the minimum angle of resolution [logMAR]) significantly improved from 0.19 \u00b1 0.12 (Snellen equivalent, 20\/31) to 0.06 \u00b1 0.16 (20\/23) at 12 months (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.005), but not in patients with CRVO (from 0.15 \u00b1 0.13 [20\/28] to 0.07 \u00b1 0.16 [20\/24]). In addition, retinal sensitivity at 12 months improved significantly in both BRVO and CRVO (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05, respectively). Central retinal thickness showed a significant reduction in both groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). There was no significant change in MD values in either group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Intravitreal aflibercept treatment using treat-and-extend regimen had a favorable visual prognosis for retinal vein occlusion\u2013related macular edema with good initial BCVA, particularly in BRVO.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004543","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:00:09Z","timestamp":1749661209000},"page":"1974-1983","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A PROSPECTIVE OBSERVATIONAL STUDY OF INTRAVITREAL AFLIBERCEPT IN RETINAL VEIN OCCLUSION WITH INITIALLY GOOD VISUAL ACUITY"],"prefix":"10.1097","volume":"45","author":[{"given":"Yusuke","family":"Koga","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Matsushita Memorial Hospital, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2347-4789","authenticated-orcid":false,"given":"Kentaro","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Kusada","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohsaku","family":"Numa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Sotozono","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250917","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/IAE.0b013e3182870c15","article-title":"Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature","volume":"33","author":"Jaulim","year":"2013","journal-title":"Retina"},{"key":"R2-20250917","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","article-title":"Natural history of branch retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"R3-20250917","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ophtha.2010.04.019","article-title":"Natural history of visual outcome in central retinal vein occlusion","volume":"118","author":"Hayreh","year":"2011","journal-title":"Ophthalmology"},{"key":"R4-20250917","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","article-title":"Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"R5-20250917","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"R6-20250917","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"key":"R7-20250917","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"R8-20250917","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R9-20250917","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"R10-20250917","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"R11-20250917","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"R12-20250917","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/IAE.0b013e3181aa8e20","article-title":"Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis","volume":"29","author":"Kondo","year":"2009","journal-title":"Retina"},{"key":"R13-20250917","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1038\/s41598-019-42982-5","article-title":"Branch retinal vein occlusion: treatment outcomes according to the retinal nonperfusion area, clinical subtype, and crossing pattern","volume":"9","author":"Iida-Miwa","year":"2019","journal-title":"Sci Rep"},{"key":"R14-20250917","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.3390\/jcm11123540","article-title":"Foveal intraretinal fluid localization affects the visual prognosis of branch retinal vein occlusion","volume":"11","author":"Sasajima","year":"2022","journal-title":"J Clin Med"},{"key":"R15-20250917","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2017.6843","article-title":"Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: secondary outcomes from the SCORE2 randomized clinical trial","volume":"136","author":"Scott","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R16-20250917","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.oret.2016.10.014","article-title":"Treat-and-Extend regimen for macular edema secondary to central retinal vein occlusion: 12-month results","volume":"1","author":"Rahimy","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"R17-20250917","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/IAE.0000000000000418","article-title":"Fundus changes in branch retinal vein occlusion","volume":"35","author":"Hayreh","year":"2015","journal-title":"Retina"},{"key":"R18-20250917","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/IAE.0000000000000256","article-title":"Fundus changes in central retinal vein occlusion","volume":"35","author":"Hayreh","year":"2015","journal-title":"Retina"},{"key":"R19-20250917","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajo.2021.01.027","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend for macular edema in central retinal vein occlusion: the CENTERA study","volume":"227","author":"Korobelnik","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R20-20250917","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00417-021-05150-y","article-title":"Prospective trial of treat-and-extend regimen with aflibercept for branch retinal vein occlusion: 1-year results of the PLATON trial","volume":"259","author":"Park","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-20250917","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ajo.2017.08.005","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion","volume":"182","author":"Mimouni","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R22-20250917","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(00)00722-4","article-title":"Perimetric sensitivity and retinal thickness in eyes with macular edema resulting from branch retinal vein occlusion","volume":"131","author":"Imasawa","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R23-20250917","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/IAE.0000000000001737","article-title":"Optical coherence tomography angiography in retinal vein occlusion: correlations between macular vascular density, visual acuity, and peripheral nonperfusion area on fluorescein angiography","volume":"38","author":"Seknazi","year":"2018","journal-title":"Retina"},{"key":"R24-20250917","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.ophtha.2016.07.008","article-title":"Visual acuity is correlated with the area of the foveal avascular zone in diabetic Retinopathy and retinal vein occlusion","volume":"123","author":"Balaratnasingam","year":"2016","journal-title":"Ophthalmology"},{"key":"R25-20250917","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ajo.2017.10.037","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion","volume":"186","author":"Eldeeb","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R26-20250917","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.oret.2020.10.016","article-title":"Visual acuity in retinal vein occlusion, diabetic, and uveitic macular edema: central subfield thickness and ellipsoid zone analysis","volume":"5","author":"Ciulla","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R27-20250917","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/APO.0000000000000598","article-title":"Update on retinal vein occlusion","volume":"12","author":"Romano","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R28-20250917","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/OPTH.S209253","article-title":"Real-world data: ranibizumab treatment for retinal vein occlusion in the OCEAN study","volume":"13","author":"Callizo","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R29-20250917","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2147\/OPTH.S344194","article-title":"Real-world data on intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 24-month outcomes","volume":"16","author":"Shimura","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R30-20250917","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.ophtha.2009.05.001","article-title":"Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year","volume":"116","author":"Kriechbaum","year":"2009","journal-title":"Ophthalmology"},{"key":"R31-20250917","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00417-020-04759-9","article-title":"The usefulness of the retinal sensitivity measurement with a microperimetry for predicting the visual prognosis of branch retinal vein occlusion with macular edema","volume":"258","author":"Fujino","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R32-20250917","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00417-011-1860-0","article-title":"Retinal sensitivity after resolution of the macular edema associated with retinal vein occlusion","volume":"250","author":"Ota","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R33-20250917","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1038\/s41598-021-84240-7","article-title":"Optical coherence tomography angiography and Humphrey field analyser for macular capillary non-perfusion evaluation in branch retinal vein occlusion","volume":"11","author":"Terashima","year":"2021","journal-title":"Sci Rep"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:01:40Z","timestamp":1758121300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004543","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"type":"print","value":"0275-004X"},{"type":"electronic","value":"1539-2864"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}